相关实验视频

Updated: Jan 8, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

通过DPP4抑制来治疗MMAE耐药膀癌的治疗策略

Gang Li¹, Shuichi Tatarano¹, Hirofumi Yoshino¹

¹Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.

Molecular oncology

|December 21, 2025

概括

对单甲基奥里斯塔丁E (MMAE) 的耐药性是膀癌治疗中的一个挑战. 用像西塔利普丁这样的抑制剂准二基酶4 (DPP4) 显示出通过影响细胞活力和生长来克服MMAE耐药性的希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

单甲基奥里斯丁E (MMAE) 是恩福图马布维多丁 (EV) 治疗膀癌 (BC) 的关键成分.
对MMAE的治疗耐药性在治疗局部发达和转移的BC.中构成了重大挑战.
了解MMAE耐药机制对于开发有效的治疗策略至关重要.

研究的目的:

研究膀癌细胞中MMAE耐药性背后的机制.
评估向二基化酶4 (DPP4) 在克服MMAE耐药性的治疗潜力.

主要方法:

建立了抗MMAE的膀癌细胞系 (MR-BCs).
RNA测序以确定MR-BCs中差异表达的基因.
用小干扰RNA (siRNA) 准DPP4.4进行基因淘汰.
在体外测试评估细胞活力,增殖,迁移,入侵,亡和细胞周期进展.
评估瘤生长抑制的体内研究.

主要成果:

在MR-BCs中,二乙酶4 (DPP4) 表达显著上调.
DPP4敲击抑制了MR-BC的活力.
作为DPP4抑制剂,西塔利普丁抑制了BC细胞的增殖,迁移和入侵.
西塔利普丁通过AKT通路的抑制增强了MMAE诱导的亡,G2M细胞循环停止和反应性氧物种的产生.
西塔利普丁显著抑制了MMAE耐药细胞的体内生长.

结论:

DPP4与膀癌中MMAE耐药性有关.
使用诸如西塔格利普丁之类的药物抑制DPP4,代表了克服BC中MMAE耐药性的潜在治疗策略.
向DPP4可能会重新敏感化抵抗MMAE治疗的膀癌细胞.

关键词:

在 AKT AKT 里面.膀癌:膀癌是一种癌症.双基酸酶 4 双基酸酶 4 单甲基奥里斯塔丁E 单甲基奥里斯塔丁E 西塔格利普丁 (Sitagliptin) 是一种

更多相关视频

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Mouse Bladder Wall Injection

Mouse Bladder Wall Injection

Published on: July 12, 2011

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...